AIM: To determine the frequency of occult hepatitis B infection (OHBI) in a group of human immunodeficiency virus (HIV)-1+/ hepatitis B surface antigen negative (HBsAg)- patients from Mexico. METHODS: We investigated the presence of OHBI in 49 HIV-1+/HBsAg- patients. Hepatitis B virus (HBV) DNA was analyzed using nested PCR to amplify the Core (C) region and by real-time PCR to amplify a region of the S and X genes. The possible associations between the variables and OHBI were investigated using Pearson's χ(2) and/or Fisher's exact test. RESULTS: We found that the frequency of OHBI was 49% among the group of 49 HIV-1+/HBsAg- patients studied. The presence of OHBI was significantly associated with the HIV-1 RNA viral load [odds ratio (OR) = 8.75; P = 0.001; 95%CI: 2.26-33.79] and with HIV-antiretroviral treatment with drugs that interfere with HBV replication (lamivudine, tenofovir or emtricitabine) (OR = 0.25; P = 0.05; 95%CI: 0.08-1.05). CONCLUSION: The OHBI frequency is high among 49 Mexican HIV-1+/HBsAg- patients and it was more frequent in patients with detectable HIV RNA, and less frequent in patients who are undergoing HIV-ARV treatment with drugs active against HBV.
AIM: To determine the frequency of occult hepatitis B infection (OHBI) in a group of human immunodeficiency virus (HIV)-1+/ hepatitis B surface antigen negative (HBsAg)- patients from Mexico. METHODS: We investigated the presence of OHBI in 49 HIV-1+/HBsAg- patients. Hepatitis B virus (HBV) DNA was analyzed using nested PCR to amplify the Core (C) region and by real-time PCR to amplify a region of the S and X genes. The possible associations between the variables and OHBI were investigated using Pearson's χ(2) and/or Fisher's exact test. RESULTS: We found that the frequency of OHBI was 49% among the group of 49 HIV-1+/HBsAg- patients studied. The presence of OHBI was significantly associated with the HIV-1 RNA viral load [odds ratio (OR) = 8.75; P = 0.001; 95%CI: 2.26-33.79] and with HIV-antiretroviral treatment with drugs that interfere with HBV replication (lamivudine, tenofovir or emtricitabine) (OR = 0.25; P = 0.05; 95%CI: 0.08-1.05). CONCLUSION: The OHBI frequency is high among 49 Mexican HIV-1+/HBsAg- patients and it was more frequent in patients with detectable HIV RNA, and less frequent in patients who are undergoing HIV-ARV treatment with drugs active against HBV.
Entities:
Keywords:
Hepatitis B surface antigen negative; Hepatitis B virus; Human immunodeficiency virus; Molecular diagnostics; Occult hepatitis B virus infection; Risk factors
Authors: R J Gilson; A E Hawkins; M R Beecham; E Ross; J Waite; M Briggs; T McNally; G E Kelly; R S Tedder; I V Weller Journal: AIDS Date: 1997-04 Impact factor: 4.177
Authors: Gerald Y Minuk; Dong-Feng Sun; Julia Uhanova; Manna Zhang; Shauna Caouette; Lindsay E Nicolle; Adam Gutkin; Karen Doucette; Bruce Martin; Antonio Giulivi Journal: J Hepatol Date: 2005-01-13 Impact factor: 25.083
Authors: C M Martin; J A Welge; N J Shire; S D Rouster; M T Shata; K E Sherman; J T Blackard Journal: J Viral Hepat Date: 2009-11-02 Impact factor: 3.728
Authors: Azwidowi Lukhwareni; Rosemary J Burnett; S Gloria Selabe; M Olga Mzileni; M Jeffrey Mphahlele Journal: J Med Virol Date: 2009-03 Impact factor: 2.327
Authors: Francisca Sosa-Jurado; Daniel Meléndez-Mena; Nora H Rosas-Murrieta; Belinda Guzmán-Flores; Miguel A Mendoza-Torres; Roberto Barcenas-Villalobos; Luis Márquez-Domínguez; Paulina Cortés-Hernández; Julio Reyes-Leyva; Verónica Vallejo-Ruiz; Gerardo Santos-López Journal: PLoS One Date: 2018-10-10 Impact factor: 3.240